
REPL Stock Forecast & Price Target
REPL Analyst Ratings
Bulls say
Replimune Group Inc has demonstrated a significant increase in the probability of regulatory approval for its lead candidate RP1 in combination with Opdivo for anti-PD1 failed melanoma patients, rising from 50% to an impressive 85%. The company reports a relatively low incidence of serious treatment-related adverse events, with only 12.8% of patients experiencing G3+ TRAEs, indicating a favorable safety profile for the therapy. Additionally, promising results from the IGNYTE trial further support the potential for approval, bolstering the company's outlook amidst competitive therapies that have shown lower overall response rates.
Bears say
Replimune Group Inc. faces significant risks related to its clinical programs, particularly for the RP1 product candidate, with concerns about the inability to generate compelling efficacy and safety data in future trials and failure to meet FDA requirements for marketing authorization resubmission. Additionally, the FDA's complete response letter (CRL) highlights critical issues with the adequacy of the IGNYTE trial, the heterogeneity of the patient population, and insufficient data to support key statistical endpoints, which could hinder regulatory approval. Furthermore, the potential for medium- to long-term dilution poses an additional financial risk that may impact investor sentiment and the company's valuation.
This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.
REPL Analyst Forecast & Price Prediction
Start investing in REPL
Order type
Buy in
Order amount
Est. shares
0 shares